GREENVILLE, SC.–(BUSINESS WIRE)–KIYATEC,
Inc. today announced that the company has opened Inova
Health System (Inova) and Roswell
Park Comprehensive Care Center as sites for its U.S. clinical study,
3D-PREDICT, to validate the company’s test as a patient-specific
predictor of response to cancer therapies in ovarian, glioblastoma (GBM)
and rare cancer patients.
“The addition of Inova Health System and Roswell Park Comprehensive
Cancer Center to our clinical study is an important milestone as we
continue on the path to determine the best drug option for cancer
patients before they begin their treatment journey,” said Matthew
Gevaert, CEO of KIYATEC. “Both hospitals are known for their excellence
in clinical research and patient care, most notably in ovarian cancer.
Not only will this be significant for our trial, it underscores their
commitment to finding the best, personalized care for their patients.”
The 3D-PREDICT clinical study analyzes a patient’s live cancer cells,
grown in KIYATEC’s laboratory within a biologically-relevant 3D
microenvironment, to determine whether those cells respond to
guideline-recommended cancer drugs. Evidence from the company’s earlier
pilot study established a correlation between patient-specific predicted
tumor response and actual patient clinical response to cancer therapy.
The 3D-PREDICT study is a fully prospective, multi-institutional effort
to validate the predictive accuracy of the test and correlate response
predictions to clinical outcomes among patients with newly diagnosed and
relapsed ovarian cancer, glioblastoma and certain rare tumors. The
3D-PREDICT study is anticipated to continue through 2022. Details on the
trial can be found on Clinicaltrials.gov.
“Roswell Park has the unique distinction of being the first clinical
center in the world to focus exclusively on cancer, and we are
continuously seeking new and improved methods to provide the best care
for our patients,” said Kunle
Odunsi, MD, PhD, FRCOG, FACOG, deputy director, chair of gynecologic
oncology and executive director of the Center for Immunotherapy, Roswell
Park Comprehensive Cancer Center, and lead investigator. “The 3D-PREDICT
trial presents an opportunity to utilize an emerging technology for
identifying biomarkers of response in our ovarian cancer immunotherapy
Inova has already accrued patients into the trial and G. Larry Maxwell,
MD, Chairman of Obstetrics and Gynecology and co-director of Inova’s
Women’s Health Integrated Research Center (WHIRC) is the lead
investigator. Inova Strategic Investments, the strategic investing
division of the Inova Health System, is an investor in KIYATEC. The
division invests in companies that align with Inova’s strategic
priorities of delivering personalized health and healthcare services.
KIYATEC will be exhibiting at the Society
for Gynecologic Oncology (SGO) 50th Annual Meeting on Women’s
Cancer, which is being held March 16-19, 2019 at the Hawaii
Convention Center in Honolulu, Hawaii.
Lauren Arnold, 781-235-3060